Intramedullary Nailing for Pathological Fractures of the Proximal Humerus.
10.4055/cios.2016.8.4.458
- Author:
Eun Seok CHOI
1
;
Ilkyu HAN
;
Hwan Seong CHO
;
In Woong PARK
;
Jong Woong PARK
;
Han Soo KIM
Author Information
1. Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea. hankim@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Humerus;
Metastasis;
Intrameullary nailing;
Pathologic fracture
- MeSH:
Follow-Up Studies;
Fracture Fixation, Intramedullary*;
Fractures, Spontaneous*;
Humans;
Humerus*;
Karnofsky Performance Status;
Methods;
Neoplasm Metastasis;
Recurrence
- From:Clinics in Orthopedic Surgery
2016;8(4):458-464
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Endoprosthetic reconstruction is widely applied for pathological fractures of the proximal humerus; however, functional impairment is usually unsatisfactory. The aims of the current study are to evaluate the reliability of interlocking intramedullary (IM) nailing with cement augmentation as a fixation method in proximal humeral lesions and to assess functional outcomes. METHODS: We reviewed 32 patients with pathological fractures of the proximal humerus who underwent interlocking IM nailing and cement augmentation. Functional scores and pain relief were assessed as outcomes. RESULTS: The mean follow-up period was 14.2 months. The mean Musculoskeletal Tumor Society functional score and Karnofsky performance status scale score were 27.7 and 75.6, respectively. Improvement of pain assessed using the visual analogue scale was 6.2 on average. Thirty-one patients (97%) experienced no pain after surgery. The mean ranges of forward flexion and abduction were 115° and 112.6°, respectively. All patients achieved stability and had no local recurrence without failure of fixation until the last follow-up. CONCLUSIONS: Proximal interlocking IM nailing with cement augmentation appears to be a reliable treatment option for pathological or impending fractures of the proximal humerus in selected patients with metastatic tumors, even with extensive bone destruction.
